Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depigoid mixed pollen immunotherapy dose-safety study in allergic rhinitis/rhinoconjunctivitis
2014-001571-31Phase 2Terminated
- Sponsor
- LETI Pharma
- Start
- Aug 2014
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Depigoid grasses mix + Olea europaea + Salsola kali in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by LETI Pharma. Primary endpoint: Immediate or delayed systemic grade 2 reactions. Started Aug 2014; status: terminated.
02
Drugs
Depigoid grasses mix + Olea europaea + Salsola kali
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2014-001571-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001571-31.